Inhibition of multidrug-resistant acinetobacter baumannii by nonviral expression of hCAP-18 in a bioengineered human skin tissue

Molecular Therapy

Volumn 17, Issue 3, 2009, Pages 562-569

  Thomas Virnig, Christina L ^a,b   Centanni, John M ^b   Johnston, Colette E ^b   He, Li Ke ^c   Schlosser, Sandy J ^a   Van Winkle, Kelly F ^c   Chen, Ruibing ^d   Gibson, Angela L ^a,d   Szilagyi, Andrea ^c   Li, Lingjun ^d   Shankar, Ravi ^c   Allen Hoffmann, B Lynn ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Stratatech Corporation   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFAZOLIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BURN INFECTION; CELL BASED GENE THERAPY; CONTROLLED STUDY; EPIDERMIS CELL; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; KERATINOCYTE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NORMAL HUMAN; PROTEIN EXPRESSION; TISSUE ENGINEERING; TISSUE SECTION;

ACINETOBACTER BAUMANNII; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BURNS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; KERATINOCYTES; MICE; MICE, NUDE; PROTEIN ENGINEERING; SKIN;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS);

EID: 61649127505     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.289     Document Type: Article

References (49)

1. Robson, MC (1997). Wound infection. A failure of wound healing caused by an imbalance of bacteria. Surg Clin North Am 77: 637-650.
2. Melstrom, KA Jr., Smith, JW, Gamelli, RL and Shankar, R (2006). New perspectives for a new century: Implications of pathogen responses for the future of antimicrobial therapy. J Burn Care Res 27: 251-264.
3. Pollack, M, Taylor, NS and Callahan, LT 3rd (1977). Exotoxin production by clinical isolates of Pseudomonas aeruginosa. Infect Immun 15 776-780.
4. McGowan, JE Jr. (2006). Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum. Am J Med 119 (6 suppl 1): S29-S36; discussion S62-S70.
5. Rice, LB (2006). Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43 (suppl. 2): S100-S105.
6. Heilborn, JD, Nilsson, MF, Kratz, G, Weber, G, Sorensen, O, Borregaard, N et al. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 120: 379-389.
7. Ong, PY, Ohtake, T, Brandt, C, Strickland, I, Boguniewicz, M, Ganz, T et al. (2002). Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347: 1151-1160.
8. Zanetti, M, Gennaro, R and Romeo, D (1995). Cathelicidins: A novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374: 1-5.
9. Yamasaki, K, Schauber, J, Coda, A, Lin, H, Dorschner, RA, Schechter, NM et al. (2006). Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 20: 2068-2080.
10. Sorensen, OE, Follin, P, Johnsen, AH, Calafat, J, Tjabringa, GS, Hiemstra, PS et al. (2001). Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97: 3951-3959.
11. Murakami, M, Lopez-Garcia, B, Braff, M, Dorschner, RA and Gallo, RL (2004). Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 172: 3070-3077.
12. Durr, UH, Sudheendra, US and Ramamoorthy, A (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta 1758: 1408-1425.
13. Oppenheim, JJ and Yang, D (2005). Alarmins: Chemotactic activators of immune responses. Curr Opin Immunol 17: 359-365.
14. De, Y, Chen, Q, Schmidt, AP, Anderson, GM, Wang, JM, Wooters, J et al. (2000). LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192: 1069-1074.
15. Carretero, M, Escamez, MJ, Garcia, M, Duarte, B, Holguin, A, Retamosa, L et al. (2008). In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 128: 223-236.
16. Lau, YF, Bowdish, DM, Cosseau, C, Hancock, RE and Davidson, DJ (2006). Apoptosis of airway epithelial cells: Human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol 34: 399-409.
17. Niyonsaba, F, Someya, A, Hirata, M, Ogawa, H and Nagaoka, I (2001). Evaluation of the effects of peptide antibiotics human beta-defensins-1/ -2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 31: 1066-1075.
18. Allen-Hoffmann, BL, Schlosser, SJ, Ivarie, CA, Sattler, CA, Meisner, LF and O'Connor, SL (2000). Normal growth and differentiation in a spontaneously immortalized neardiploid human keratinocyte cell line, NIKS. J Invest Dermatol 114: 444-455.
19. Kaus, A, Jacobsen, F, Sorkin, M, Rittig, A, Voss, B, Daigeler, A et al. (2008). Host defence peptides in human burns. Burns 34 32-40.
20. Rosenberg, SA, Aebersold, P, Cornetta, K, Kasid, A, Morgan, RA, Moen, R et al. (1990). Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578.
21. Till, BG, Jensen, MC, Wang, J, Chen, EY, Wood, BL, Greisman, HA et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112: 2261-2271.
22. Heslop, H (2007). Giving Gene Marked (Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients With Relapsed EBV-Positive Lymphoma, (ANGEL). Food and Drug Administration. Report no. NCT00058617 .
23. Shin, SI, Freedman, VH, Risser, R and Pollack, R (1975). Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72: 4435-4439.
24. Neely, AN, Brown, RL, Clendening, CE, Orloff, MM, Gardner, J and Greenhalgh, DG (1997). Proteolytic activity in human burn wounds. Wound Repair Regen 5: 302-309.
25. Prager, MD, Baxter, CR and Hartline, B (1994). Proteolytic activity in burn wound exudates and comparison of fibrin degradation products and protease inhibitors in exudates and sera. J Burn Care Rehabil 15: 130-136.
26. Armstrong, DG and Jude, EB (2002). The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 92: 12-18.
27. He, Y, Young, PK and Grinnell, F (1998). Identification of proteinase 3 as the major caseinolytic activity in acute human wound fluid. J Invest Dermatol 110: 67-71.
28. Oren, A, Ganz, T, Liu, L and Meerloo, T (2003). In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 74: 180-182.
29. Braff, MH, Di Nardo, A and Gallo, RL (2005). Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 124: 394-400.
30. Bera, A, Biswas, R, Herbert, S and Gotz, F (2006). The presence of peptidoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity. Infect Immun 74: 4598-4604.
31. Cohen, MJ, Carroll, C, He, LK, Muthu, K, Gamelli, RL, Jones, SB et al. (2007). Severity of burn injury and sepsis determines the cytokine responses of bone marrow progenitor-derived macrophages. J Trauma 62: 858-867.
32. Muthu, K, He, LK, Melstrom, K, Szilagyi, A, Gamelli, RL and Shankar, R (2008). Perturbed bone marrow monocyte development following burn injury and sepsis promote hyporesponsive monocytes. J Burn Care Res 29 12-21.
33. Cohen, MJ, Shankar, R, Stevenson, J, Fernandez, R, Gamelli, RL and Jones, SB (2004). Bone marrow norepinephrine mediates development of functionally different macrophages after thermal injury and sepsis. Ann Surg 240: 132-141.
34. Shankar, R, He, LK, Szilagyi, A, Muthu, K, Gamelli, RL, Filutowicz, M et al. (2007). A novel antibacterial gene transfer treatment for multidrug-resistant Acinetobacter baumannii-induced burn sepsis. J Burn Care Res 28: 6-12.
35. Andreadis, ST (2007). Gene-modified tissue-engineered skin: The next generation of skin substitutes. Adv Biochem Eng Biotechnol 103 241-274.
36. MacNeil, S (2007). Progress and opportunities for tissue-engineered skin. Nature 445: 874-880.
37. Horch, RE, Kopp, J, Kneser, U, Beier, J and Bach, AD (2005). Tissue engineering of cultured skin substitutes. J Cell Mol Med 9: 592-608.
38. Jacobsen, F, Mittler, D, Hirsch, T, Gerhards, A, Lehnhardt, M, Voss, B et al. (2005). Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. Gene Ther 12: 1494-1502.
39. Zaiou, M, Nizet, V and Gallo, RL (2003). Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 120: 810-816.
40. Carretero, M, Del Rio, M, Garcia, M, Escamez, MJ, Mirones, I, Rivas, L et al. (2004). A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. FASEB J 18: 1931-1933.
41. Koczulla, R, von Degenfeld, G, Kupatt, C, Krotz, F, Zahler, S, Gloe, T et al. (2003). An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111: 1665-1672.
42. Steinstraesser, L, Ring, A, Bals, R, Steinau, HU and Langer, S (2006). The human host defense peptide LL37/hCAP accelerates angiogenesis in PEGT/PBT. Ann Plast Surg 56: 93-98.
43. Lande, R, Gregorio, J, Facchinetti, V, Chatterjee, B, Wang, YH, Homey, B et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-569.
44. Larrick, JW, Hirata, M, Balint, RF, Lee, J, Zhong, J and Wright, SC (1995). Human CAP18: A novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 63: 1291-1297.
45. Cirioni, O, Giacometti, A, Ghiselli, R, Bergnach, C, Orlando, F, Silvestri, C et al. (2006). LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 50: 1672-1679.
46. Schroder, JM (1999). Epithelial peptide antibiotics. Biochem Pharmacol 57: 121-134.
47. Zasloff, M (2002). Antimicrobial peptides of multicellular organisms. Nature 415: 389-395.
48. Hornef, MW, Wick, MJ, Rhen, M and Normark, S (2002). Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 3: 1033-1040.
49. Walker, HL and Mason, AD Jr. (1968). A standard animal burn. J Trauma 8: 1049-1051.